Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: A phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 324-330

  Comella, Pasquale ^a   Filippelli, G ^b   De Cataldis, G ^c   Massidda, B ^d   Frasci, G ^a   Maiorino, L ^e   Putzu, C ^f   Mancarella, S ^b   Palmeri, S ^g   Cioffi, R ^h   Roselli, M ⁱ   Buzzi, F ^j   Milia, V ^b   Gambardella, A ^k   Natale, D ^b   Bianco, M ^l   Ghiani, M ^m   Masullo, P ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Cities   (Italy)

^c Ospedale G da Procida   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e San Gennaro Hospital   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h City Hospital   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j City Hospital   (Italy)

^k SECOND UNIVERSITY OF NAPLES   (Italy)

^l Ospedale S Leonardo   (Italy)

^m City Hospital   (Italy)

more..

Author keywords

Cisplatin; Gemcitabine; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; NAVELBINE; PACLITAXEL; RANITIDINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREATHING RATE; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIBEROPTIC BRONCHOSCOPY; FREQUENCY ANALYSIS; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SKIN TOXICITY; STOMATITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; VINBLASTINE;

EID: 33847295600     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl396     Document Type: Article

References (35)

1. Non-small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patient data from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
2. Marino P, Pampallona S, Preatoni A et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
4. Cullen M, Billingham J, Woodraffe C et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
5. Spiro SG, Rudd RM, Souhami RL et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax 2004; 59: 828-836.
6. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European Multicenter Trial including 612 patients. J Clin Oncol 1994; 12: 360-366.
7. Crinò L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
8. Bonomi P, Kim K, Fairclough D et al, Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
9. Georgoulias V, Androulakis N, Dimopoulos AM et al. First-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. Ann Oncol 1998; 9: 331-334.
10. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
11. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
12. Smit EF, van Meerbeeck JPAM, Lianes P et al. Three-arm randomized study of two cisplatin-based regimen and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 31: 3909-3917.
13. Comella P, Frasci G, Panza N et al. Cisplatin-gemcitabine-vinorelbine combination therapy in advanced NSCLC: A phase II randomised study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17: 1526-1534.
14. Frasci G, Panza N, Comella P et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small cell lung cancer. A phase I-II study. J Clin Oncol 1999; 17: 2316-2325.
15. Comella P, Frasci G, Panza N et al. Randomized trial comparing cisplatin gemcitabine and vinorelbine, with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer. Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18: 1451-1457.
16. Comella P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001; 28 (Suppl 7): 7-10.
17. Crino' L, Scagliotti G, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. A randomized phase III study. J Clin Oncol 1999; 17: 3522-3530.
18. Souquet PJ, Tan EH, Rodrigues Pereira J et al. GLOB 1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer. Ann Oncol 2002; 13: 1853-1861.
19. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: A Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
20. Rudd RM, Gower NH, Spiro SG et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide and cisplatin in stage IIIB or IV non-small cell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23: 142-153.
21. Laack E, Dickgreber N, Müller T et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004; 22: 2348-2356.
22. Paccagnella A, Oniga F, Bearz A et al. Adding gemcitabine to paclitaxel/ carboplatin combination increases survival in advanced non-small cell lung cancer: Results of a phase II-III study. J Clin Oncol 2006; 24: 681-687.
23. Delbaldo C, Michiels S, Syz N et al. Benefit of adding a drug to a single agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: A meta-analysis. JAMA 2004; 292: 470-484.
24. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer. Lancet 2001; 357: 1478-1484.
25. Kosmidis P, Mylonakis N, Nicolaides C et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 3578-3585.
26. Gridelli C, Gallo C, Shepherd F et al. Gemcitabine plus vinorelbine, compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer. A phase III trial of the Italian GEMVIN Investigators and the Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
27. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III randomized trial. J Clin Oncol 2005; 23: 2937-2945.
28. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
29. Kaplan ES, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 557-580.
30. Mantel N. Evaluation of survival data and two new ranks of order statistics arising in its considerations. Cancer Chemother Rep 1966; 50: 163-170.
31. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
32. Cochran WG. Some methods for strengthening the common chi-square test. Biometrics 1954; 10: 417-451.
33. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer. A meta-analysis of published literature. J Clin Oncol 2005; 23: 2926-2936.
34. Kroep JR, Giaccone G, Voom DA et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol 1999; 17: 2190-2197.
35. Comella P, Frasci G, Carnicelli P et al. Gemcitabine with either paclitaxel or vinorelbine versus paclitaxel or gemcitabine alone for elderly or unfit advanced non-small cell lung cancer patients. Br J Cancer 2004; 91: 489-497.